Home » Pharma News (page 15)

Pharma News

Chemotherapeutic coatings enhance tumour-frying nanoparticles: Study

Chemotherapeutic coatings enhance tumour-frying nanoparticles: Study The photothermal therapy is already being tested for several types of cancers in clinical trials conducted by Nanospectra Biosciences Researchers at Duke University have devised a method for making a promising nanoscale cancer treatment even more deadly to tumours. The invention allows an extremely thin layer of hydrogels (think contact lenses) to be deposited on ... Read More »

Union Minister of Chemicals and Fertilisers launches pharma price data bank

Union Minister of Chemicals and Fertilisers launches pharma price data bank Pharma price data bank is an integrated pharmaceutical database management system, managed and operated by National Pharmaceutical Pricing Authority The Union Minister of Chemicals and Fertilisers, Ananth Kumar launched pharma price data bank. It is an integrated pharmaceutical database management system, managed and operated by National Pharmaceutical Pricing Authority (NPPA). ... Read More »

AGTC Catapults Premarket on $1 Billion+ Eye Disease Pact With Biogen

AGTC Catapults Premarket on $1 Billion+ Eye Disease Pact With Biogen CAMBRIDGE, Mass. — Biogen, Inc. and AGTC (AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, entered into an agreement worth more than $1 billion to develop gene-based therapies for multiple ophthalmic diseases, the two companies announced this morning. ... Read More »

Novartis agrees to buy Spinifex Pharmaceuticals for more than $200m

Novartis agrees to buy Spinifex Pharmaceuticals for more than $200m Swiss drugmaker Novartis has strengthened its presence in pain management by agreeing to acquire a US-Australia biotech firm Spinifex Pharmaceuticals for more than $200m. Spinifex is focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a new angiotensin II Type 2 receptor (AT2R) antagonist. EMA401 is ... Read More »

Siemens, BioNTech to develop new personalized cancer vaccines

Siemens, BioNTech to develop new personalized cancer vaccines Siemens has entered into a strategic collaboration with BioNTech for the good manufacturing practice (GMP) production of personalized cancer vaccines. Under the deal, BioNTech’s subsidiaries, BioNTech RNA Pharmaceuticals and EUFETS, will work with Siemens to build a fully automated and digitalized production site to provide capacity for BioNTech’s personalized cancer vaccines to ... Read More »

AbCheck and Pierre Fabre Enter Into Strategic Research Partnership

AbCheck and Pierre Fabre Enter Into Strategic Research Partnership  AbCheck s.r.o, a wholly owned subsidiary of Affimed N.V., Heidelberg, Germany, and Pierre Fabre Pharmaceuticals have expanded their ongoing collaboration into a strategic research partnership in the field of human antibody discovery and optimization. Under the expanded agreement, AbCheck will use its proprietary human antibody discovery and optimization platform technologies, AbSieve ... Read More »

SPARC licenses Xelpros to Sun Pharma for US market

SPARC licenses Xelpros to Sun Pharma for US market Sun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the US market. In addition to up-front payment of USD 3 million, SPARCBSE 2.83 % will receive certain other milestone payments, both totaling to USD 16 million from Sun Pharma, ... Read More »

Cipla’s Stempeutics gets process patent for Stempeucel from Japan

Cipla’s Stempeutics gets process patent for Stempeucel from Japan Drug major Cipla today said its JV firm Stempeutics Research has received process patent from the Japan Patent Office for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia (CLI). Stempeutics chief operating officer B N Manohar said: “The new patent strengthens our position in Japan, which have ... Read More »

Enter Sun Pharma for long term

Enter Sun Pharma for long term, says Sandeep Shenoy Sandeep Shenoy of Pioneer Investcorp told CNBC-TV18, ” Sun Pharmaceutical Industries  is a well-run company where the business models are not impeded, I don’t think the glitches make much of a problem on their business model. Any leader of a sector where there is a small stumble and you get a ... Read More »

Lupin submits fresh studies for two products suspended by EMA

Lupin submits fresh studies for two products suspended by EMA Drug firm LupinBSE 0.01 % has submitted fresh studies to the European Medicines Agency (EMA) for two products, which are among 700 generic drugs suspended by the health regulator due to flawed clinical trial data provided by GVK Bio. “The company has successfully conducted the new bio equivalence (BE) studies ... Read More »

BIGTheme.net • Free Website Templates - Downlaod Full Themes